Sponsors (3)
Official title: To amend the Controlled Substances Act to modify requirements relating to the prescription of controlled substances by means of the internet, and for other purposes.
The bill substantially expands access to psychiatric and other controlled medications via telehealth and simplifies cross‑state practice—improving timely care for many patients—while imposing federal standards and provider requirements that raise costs, reduce state/local control, and heighten risks of diversion and uneven protections unless monitoring and enforcement are strengthened.
Patients with mental health conditions, substance use disorders, and other chronic conditions—especially in rural and underserved areas—gain faster, easier access to FDA‑approved psychiatric and other controlled medications through single telehealth visits and reduced interstate barriers.
Telehealth clinicians and companies can more easily provide care across state lines—reducing licensing and DEA registration burdens—making it simpler for clinicians to reach patients nationwide and for telehealth firms to operate compliantly.
Individuals and businesses operating under the Act get uniform federal protection against conflicting state bans, creating legal certainty that authorized telehealth activities will be permitted nationwide.
Patients and communities face increased risk of inappropriate prescribing and diversion of controlled substances as telehealth prescribing of those drugs expands, unless monitoring and safeguards are significantly strengthened.
States and localities lose tools to enforce stricter licensing or registration rules (including local DEA registration and independent oversight), which can weaken local control and create uneven patient protections across states.
Extensive telehealth staffing, accreditation, monitoring, and compensation mandates will raise operational costs and compliance complexity for telehealth providers, likely increasing prices or reducing availability of low‑cost providers and squeezing small startups.
Based on analysis of 5 sections of legislative text.
Allows telehealth evaluations to validate prescriptions for certain FDA‑approved non‑narcotic mental health controlled substances, eases DEA/state registration limits, and permits limited interstate telepsychiatry with malpractice/licensure accommodations.
Introduced January 9, 2026 by Neal Patrick Dunn · Last progress January 9, 2026
Expands when psychiatrists and other licensed clinicians can prescribe certain controlled medications after evaluations conducted by telehealth, creates definitions and exemptions for telehealth entities, and lets telehealth clinicians use a telehealth employer address for DEA registration. It also allows covered psychiatrists to provide telehealth services across state lines when licensure and malpractice coverage are substantially similar, and preempts state laws that would restrict these activities. The bill mainly changes federal controlled-substance and telehealth rules to broaden telemedicine prescribing for FDA‑approved non‑narcotic mental health drugs and to ease interstate telepsychiatry practice and DEA registration logistics; several provisions take effect on enactment and federal law preempts conflicting state restrictions.